Cooper, Mark E.

Pathogenesis of diabetic nephropathy

Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 219

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database

Packham, D. K., Alves, T. P., Dwyer, J. P., Atkins, R., de Zeeuw, D., Cooper, M., Shahinfar, S., Lewis, J. B., & Lambers Heerspink, H. J. (2012) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 205

Comparison of different measures of urinary protein excretion for prediction of renal events

Lambers Heerspink, H. J., Gansevoort, R. T., Brenner, B. M., Cooper, M. E., Parving, H. H., Shahinfar, S., & de Zeeuw, D. (2010) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 193

Distinguishing Hyperglycemic Changes by Set7 in Vascular Endothelial Cells

Okabe, J., Orlowski, C., Balcerczyk, A., Tikellis, C., Thomas, M. C., Cooper, M. E., & El-Osta, A. (2012) · Circulation Research

Epigenetics and DNA MethylationGenomics and Chromatin Dynamics

Cited by 180

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 164

Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation

Sourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 143

Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?

Coughlan, M. T., Thallas-Bonke, V., Pete, J., Long, D. M., Gasser, A., Tong, D. C. K., Arnstein, M., Thorpe, S. R., Cooper, M. E., & Forbes, J. M. (2007) · Endocrinology

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 124

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes

Mohammedi, K., Woodward, M., Marre, M., Colagiuri, S., Cooper, M., Harrap, S., Mancia, G., Poulter, N., Williams, B., Zoungas, S., et al. (2017) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 111

Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes

Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 110

The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial

Nguyen, T. N., Harris, K., Woodward, M., Chalmers, J., Cooper, M., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., et al. (2021) · Diabetes Care

Diabetes Treatment and ManagementFrailty in Older Adults

Cited by 72

NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis

Di Marco, E., Gray, S. P., Kennedy, K., Szyndralewiez, C., Lyle, A. N., Lassègue, B., Griendling, K. K., Cooper, M. E., Schmidt, H. H. H. W., & Jandeleit-Dahm, K. A. M. (2016) · Free Radical Biology and Medicine

Nitric Oxide and Endothelin EffectsAtherosclerosis and Cardiovascular Diseases

Cited by 67

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes

Tikellis, C., Pickering, R., Tsorotes, D., Du, X.-J., Kiriazis, H., Nguyen-Huu, T.-P., Head, G. A., Cooper, M. E., & Thomas, M. C. (2012) · Clinical Science

Renin-Angiotensin System StudiesEicosanoids and Hypertension Pharmacology

Cited by 57

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial

Ohkuma, T., Jun, M., Rodgers, A., Cooper, M. E., Glasziou, P., Hamet, P., Harrap, S., Mancia, G., Marre, M., Neal, B., et al. (2019) · Hypertension

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 56

Amylin Stimulates Plasma Renin Concentration in Humans

Cooper, M. E., McNally, P. G., Phillips, P. A., & Johnston, C. I. (1995) · Hypertension

Renin-Angiotensin System StudiesAdipokines, Inflammation, and Metabolic Diseases

Cited by 50

Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes

Qin, J., Zhang, Z., Liu, J., Sun, L., Hu, L., Cooper, M. E., & Cao, Z. (2003) · Kidney International

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 42

Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes

Gueguen, C., Burke, S. L., Barzel, B., Eikelis, N., Watson, A. M. D., Jha, J. C., Jackson, K. L., Sata, Y., Lim, K., Lambert, G. W., et al. (2020) · Diabetologia

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 38

Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE−/− mice

Di Marco, E., Gray, S. P., Chew, P., Kennedy, K., Cooper, M. E., Schmidt, H. H. H. W., & Jandeleit-Dahm, K. A. M. (2016) · Clinical Science

Nitric Oxide and Endothelin EffectsAtherosclerosis and Cardiovascular Diseases

Cited by 37

Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications

Rasaratnam, N., Salim, A., Blackberry, I., Cooper, M. E., Magliano, D. J., van Wijngaarden, P., Varadarajan, S., Sacre, J. W., & Shaw, J. E. (2024) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes Management and Research

Cited by 36

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 24

Dialysis delayed is death prevented: A clinical perspective on the RENAAL study

Thomas, M. C., Cooper, M. E., Shahinfar, S., & Brenner, B. M. (2003) · Kidney International

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 22